Drug General Information |
Drug ID |
D06BYR
|
Former ID |
DNC005841
|
Drug Name |
N-Hydroxy-4-oxo-4-(4-phenoxy-phenyl)-butyramide
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C16H15NO4
|
Canonical SMILES |
C1=CC=C(C=C1)OC2=CC=C(C=C2)C(=O)CCC(=O)NO
|
InChI |
1S/C16H15NO4/c18-15(10-11-16(19)17-20)12-6-8-14(9-7-12)21-13-4-2-1-3-5-13/h1-9,20H,10-11H2,(H,17,19)
|
InChIKey |
NOELKUBXWDTLKR-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
Interstitial collagenase |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
PPAR signaling pathway
|
Pathways in cancer
|
Bladder cancer
|
Rheumatoid arthritis
|
NetPath Pathway
|
IL1 Signaling Pathway
|
EGFR1 Signaling Pathway
|
TWEAK Signaling Pathway
|
Wnt Signaling Pathway
|
PANTHER Pathway
|
Alzheimer disease-presenilin pathway
|
Plasminogen activating cascade
|
Pathway Interaction Database
|
Endothelins
|
Validated transcriptional targets of AP1 family members Fra1 and Fra2
|
Glucocorticoid receptor regulatory network
|
AP-1 transcription factor network
|
Syndecan-1-mediated signaling events
|
Reactome
|
Collagen degradation
|
Degradation of the extracellular matrix
|
Activation of Matrix Metalloproteinases
|
Basigin interactions
|
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
|
WikiPathways
|
TGF beta Signaling Pathway
|
Bladder Cancer
|
Activation of Matrix Metalloproteinases
|
Degradation of collagen
|
Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis
|
Oncostatin M Signaling Pathway
|
Prostate Cancer
|
Integrated Breast Cancer Pathway
|
Integrated Cancer pathway
|
Cell surface interactions at the vascular wall
|
Matrix Metalloproteinases
|
References |
REF 1 | J Med Chem. 2005 Oct 20;48(21):6585-96.Receptor flexibility in de novo ligand design and docking. |